|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
b11750605 |
| 003 |
CoU |
| 006 |
m o d f |
| 007 |
cr ||||||||||| |
| 008 |
210204s2020 dcu ob f000 0 eng c |
| 005 |
20250117011043.1 |
| 035 |
|
|
|a (OCoLC)ocn1236127609
|
| 040 |
|
|
|a GPO
|b eng
|e rda
|e pn
|c GPO
|d OCLCO
|d OCLCF
|d DWP
|d GPO
|d MvI
|
| 042 |
|
|
|a pcc
|
| 043 |
|
|
|a n-us---
|
| 049 |
|
|
|a GDWR
|
| 074 |
|
|
|a 1008-I (online)
|
| 086 |
0 |
|
|a Y 1.1/8:116-694
|
| 110 |
1 |
|
|a United States.
|b Congress.
|b House.
|b Committee on the Judiciary,
|e author.
|0 http://id.loc.gov/authorities/names/n79036854
|
| 245 |
1 |
0 |
|a Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act :
|b report (to accompany H.R 2374) (Including cost estimate of the Congressional Budget Office).
|
| 264 |
|
1 |
|a [Washington, D.C.] :
|b [U. S. Government Publishing Office],
|c 2020.
|
| 300 |
|
|
|a 1 online resource (10 pages).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent.
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia.
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier.
|
| 490 |
1 |
|
|a Report / 116th Congress, 2d session, House of Representatives ;
|v 116-694
|
| 500 |
|
|
|a "December 24, 2020."
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 588 |
|
|
|a Description based on online resource; title from PDF title screen (govinfo web site, viewed on Feb. 4, 2021)
|
| 650 |
|
0 |
|a Generic drugs
|z United States.
|0 http://id.loc.gov/authorities/subjects/sh2009125738
|
| 650 |
|
0 |
|a Drug approval
|z United States.
|0 http://id.loc.gov/authorities/subjects/sh2009123884
|
| 650 |
|
7 |
|a Drug approval.
|2 fast
|0 fst00898661
|
| 650 |
|
7 |
|a Generic drugs.
|2 fast
|0 fst00939969
|
| 651 |
|
7 |
|a United States.
|2 fast
|0 fst01204155
|
| 655 |
|
7 |
|a Legislative materials.
|2 fast
|0 fst01774285
|
| 655 |
|
7 |
|a Legislative materials.
|2 lcgft
|0 http://id.loc.gov/authorities/genreForms/gf2011026362
|
| 776 |
0 |
8 |
|i Print version:
|a United States. Congress. House. Committee on the Judiciary.
|t Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
|w (OCoLC)1251642711.
|
| 856 |
4 |
0 |
|u https://purl.fdlp.gov/GPO/gpo151127
|z Online Access
|
| 810 |
1 |
|
|a United States.
|b Congress.
|b House.
|t Report ;
|v 116-694.
|0 http://id.loc.gov/authorities/names/n42025618
|
| 907 |
|
|
|a .b117506059
|b 06-12-23
|c 03-08-21
|
| 944 |
|
|
|a MARS - RDA ENRICHED
|
| 998 |
|
|
|a web
|b 03-08-21
|c -
|d m
|e -
|f eng
|g dcu
|h 0
|i 2
|
| 948 |
|
|
|a bslw23/24 : jul : ess (never sent)
|
| 999 |
f |
f |
|i d67110d3-e063-580f-b1d0-be65fd52173b
|s ec14db75-a54e-537a-b59b-4a321692b578
|
| 952 |
f |
f |
|p Can circulate
|a University of Colorado Boulder
|b Online
|c Online
|d Online
|e Y 1.1/8:116-694
|h Superintendent of Documents classification
|i web
|n 1
|
